B
Björn Vandewalle
Researcher at Katholieke Universiteit Leuven
Publications - 21
Citations - 248
Björn Vandewalle is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Estimator & Cost effectiveness. The author has an hindex of 7, co-authored 18 publications receiving 219 citations. Previous affiliations of Björn Vandewalle include Universidade Nova de Lisboa.
Papers
More filters
Journal ArticleDOI
A robust estimator for the tail index of Pareto-type distributions
TL;DR: A robust estimator of the tail index is proposed, by combining a refinement of the Pareto approximation for the conditional distribution of relative excesses over a large threshold with an integrated squared error approach on partial density component estimation.
Journal ArticleDOI
On univariate extreme value statistics and the estimation of reinsurance premiums
Björn Vandewalle,Jan Beirlant +1 more
TL;DR: In this article, the estimation of insurance premiums for excess-of-loss reinsurance policies in excess of a high retention level is considered, where Wang's premium principle and heavy-tailed distributions are considered.
Book ChapterDOI
A Robust Estimator of the Tail Index Based on an Exponential Regression Model
TL;DR: In this paper, a soil database quality management project, where in the background of Pareto-type tails, automatic identification of suspicious data is needed, is motivated by a data mining project.
Journal ArticleDOI
Social and economic value of Portuguese community pharmacies in health care
Jorge Félix,Diana L. Santos Ferreira,Marta Afonso-Silva,Marta Vargas Gomes,César Ferreira,Björn Vandewalle,Sara Marques,M Mota,Suzete Costa,Maria Cary,Ines Teixeira,Ema Paulino,Bruno Macedo,Carlos Maurício Barbosa +13 more
TL;DR: Community pharmacies services provide considerable benefit in quality of life (QoL) and economic value and an increase range of services including a greater integration in primary and secondary care, among other transversal services, may add further social and economicvalue to the society.
Journal ArticleDOI
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.
TL;DR: STRs continue to represent good value for money under contemporary cost-effectiveness thresholds despite substantial price reductions of generic medications in the U. S. settings.